|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2009-3-25
|
|
pubmed:abstractText |
The authors explored the association of skin toxicity (ST) severity as measured by patient-reported ST and Common Terminology Criteria for Adverse Events (CTCAE) grading with efficacy of panitumumab, a fully human antiepidermal growth factor receptor antibody, from a phase 3 metastatic colorectal cancer (CRC) trial.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
(c) 2009 American Cancer Society
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
115
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1544-54
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:19189371-Antibodies, Monoclonal,
pubmed-meshheading:19189371-Colorectal Neoplasms,
pubmed-meshheading:19189371-Disease-Free Survival,
pubmed-meshheading:19189371-Genes, ras,
pubmed-meshheading:19189371-Humans,
pubmed-meshheading:19189371-Mutation,
pubmed-meshheading:19189371-Quality of Life,
pubmed-meshheading:19189371-Receptor, Epidermal Growth Factor,
pubmed-meshheading:19189371-Skin Diseases,
pubmed-meshheading:19189371-Survival Analysis,
pubmed-meshheading:19189371-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy.
|
|
pubmed:affiliation |
Department of HepatoGastroenterology, Digestive Oncology Unit, Ghent University Hospital, Ghent, Belgium. marc.peeters@ugent.be
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
